DisCoVeRy trial of Verklury concluded there was no clinical benefit in hospitalised patients with COVID 19 – Gilead Sciences

A study conducted in Europe of Gilead’s Verklury (remdesivir) concluded that the antiviral provided no clinical benefit in hospitalized patients with COVID-19 compared to existing treatments . The phase III open-label DisCoVeRy trial included patients admitted to hospital with laboratory-confirmed SARS-CoV-2 and if they had evidence of pneumonia or required oxygen. Participants were randomized to standard of care alone or in combination with remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, or hydroxychloroquine.Clinical status at day 15 measured by the WHO seven-point ordinal scale.

See; ” Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase III, randomised, controlled, open-label trial”.; The Lancet Infectious Diseases.Published: September 14, 2021 Florence AderMaude Bouscambert-DuchampMaya HitesNathan Peiffer-SmadjaJulien PoissyDrifa Belhadiand others.